Small Cell Lung Cancer: What To Know About Early Detection
- Mark McCartney, a 67-year-old man form Florida, skipped the doctor for 35 years. When his family finally got him to a checkup, doctors found aggressive small cell lung cancer, and after chemotherapy and radiation his scans now show no evidence of active cancer.
- Small cell lung cancer (SCLC) represents only 10-15% of all cases of lung cancer. However, it is considered one of the fastest-growing types.
- Because it often causes no pain or symptoms until late in its course, early detection remains challenging. Most patients are diagnosed after the cancer has already spread. Additionally, due to the fast speed at which small cell lung cancer grows, every step of the diagnosis and treatment process must move quickly.
- Within the next few years, lung cancer screening programs could evolve to include blood-based markers that identify fast-growing subtypes of cancer like SCLC earlier, allowing treatment while the disease is still in early stages.
After chemotherapy and radiation, his scans now show no evidence of active cancer, and McCartney hopes his story will encourage others to get regular checkups.
Read More
McCartney had reason to worry. Doctors often describe SCLC as a cancer that “moves fast and hides well.” It isn’t the most common form of lung cancer, but it’s one of the most aggressive, and that speed is exactly what makes it so hard to catch before it progresses.
“When it develops, it really doesn’t lead to symptoms until it’s already: the cat is out of the bag,” Dr. Balazs Halmos, the director of thoracic oncology at Montefiore Einstein Comprehensive Cancer Center in New York, tells SurvivorNet.
“We do not have pain fibers in the lungs. We don’t feel it until it starts blocking something, your air pipe, swallowing tube, or starts spreading into places where it can cause pain.”
That nuance on how SCLC starts and spreads means that by the time most patients know something is wrong, the cancer has often already moved beyond the lung.
McCartney, a senior project manager at JWR Construction Services and a longtime smoker, had no cough, shortness of breath or unusual fatigue before his diagnosis. “I never felt sick, so I never went to the doctor,” he explained to Baptist Health
Why Is Small Cell Lung Cancer So Hard To Detect?
A CT scan found a mass in his right lung, and a biopsy confirmed small cell lung cancer, a disease most strongly linked to smoking. McCartney, who had smoked for about 50 years, learned that his cancer was confined to the upper lobe of his right lung with no sign of lymph node involvement.
After chemotherapy and radiation at Baptist Health’s Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, McCartney’s tumor shrank from just over 5 centimeters to about 1, and follow-up scans showed no evidence of active cancer.
Because SCLC can return or spread to the brain, he’s monitored with chest CTs, brain MRIs and blood tests, and he’s now on immunotherapy, a follow-up approach that improved survival over placebo in the ADRIATIC clinical trial of durvalumab (sold under the brand name Imfinzi).
Expert Lung Cancer Resources
- A New Treatment Cuts the Risk of Early-Stage Lung Cancer Coming Back by 83% — But Only If Doctors Test for the Right Gene
- A New Wave Of Treatments Is Providing Hope For Small Cell Lung Cancer Patients
- Genetic Testing Can Help Determine Your Lung Cancer Treatment
- Black Americans Don’t Get Screened or Treated for Lung Cancer at Same Rates as White Americans: Here’s Why, & What We Can Do About It
- Diagnosing Lung Cancer and Determining Treatment
- Lung Cancer Treatment May Become More Adaptive With a Simple Blood Test
- How Does Molecular Testing Help Determine the Best Lung Cancer Treatment Option?
The ADRIATIC trial, a large phase III study (the kind of study considered high-level evidence), enrolled 730 patients with stage I to III limited-stage SCLC whose cancer hadn’t progressed after chemotherapy and radiation, and randomly assigned them to Imfinzi alone, Imfinzi plus tremelimumab, or a placebo.
Compared with the placebo group, patients on Imfinzi lived longer without their cancer worsening (16.6 vs. 9.2 months) and lived longer overall (55.9 vs. 33.4 months), with similar rates of severe side effects.
“The ADRIATIC trial is a landmark study and provides a new standard of care for patients with early-stage small cell lung cancer,” Dr. Lauren Byers, a professor and thoracic section chief at the University of Texas MD Anderson Cancer Center in Houston, said at a press briefing during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Byers was not involved in the trial.
She noted that the survival gain of nearly two years stood out, compared with the gains of roughly two months seen with immunotherapy in extensive-stage SCLC.
Imfinzi (generic name: durvalumab), an immune checkpoint inhibitor, works by helping the immune system recognize and attack cancer cells. It is now FDA-approved for people with limited-stage SCLC whose cancer has not progressed after chemotherapy and radiation.
His Advice: Don’t Wait Decades
McCartney quit smoking within about two weeks of his diagnosis and had his first colonoscopy at 67. “At the very least, don’t go 35 years without seeing a doctor,” he said.
His story is a reminder that lung cancer can grow silently, which is why screening matters. According to the U.S. Preventive Services Task Force (USPSTF), adults ages 50 to 80 who have a 20 pack-year smoking history and either still smoke or quit within the past 15 years should get a yearly low-dose CT scan.
A pack-year is a way of measuring how much someone has smoked over their lifetime. Smoking one pack a day for a year equals one pack-year, so someone who smoked a pack a day for 20 years, or two packs a day for 10 years, would meet the threshold.
If you fit these criteria, or aren’t sure whether you do, talk with your doctor about whether lung cancer screening is right for you.
Diagnosing Small Cell Lung Cancer
Unlike cancers that form slow-growing masses, small cell lung cancer starts in the neuroendocrine cells of the lung, which divide quickly and can spread through the bloodstream early on. Studies suggest these tumors can double in size in about a month, making SCLC one of the fastest-growing tumor types.
But the main concern is that SCLC is quiet. The lungs themselves have no pain nerves, so tumors can grow unnoticed until they start to block the airways or spread to areas like the chest wall (where there are pain nerves), liver or brain, where symptoms appear suddenly and often severely. “So just by the nature of where it’s coming from, it leads to a late diagnosis and from that on it can rapidly progress and cause serious trouble,” Dr. Halmos says.
Common first signs of SCLC include:
- Persistent cough
- Shortness of breath
- Hoarseness
- Unexplained weight loss
- Bone pain
Unfortunately, these signs typically appear after the disease has already advanced. About two out of three people with SCLC are diagnosed at the extensive stage, meaning it has spread beyond one side of the chest, according to the American Cancer Society (ACS).
Because small cell lung cancer grows and spreads so fast, every step of diagnosis and treatment must move quickly.
“Starting treatment quickly is critical,” Dr. Halmos says. “We certainly want to make sure, as treatment teams, to put patients through the diagnostic pathways as quickly as possible.”
That sense of urgency comes from experience. Without treatment, median survival for advanced SCLC can be as short as two to four months. With modern treatment, median survival is about a year for extensive-stage disease and roughly 25 to 30 months for limited-stage disease treated with chemotherapy and radiation, and about 29% to 34% of people with limited-stage SCLC live at least five years. In the ADRIATIC trial, adding Imfinzi pushed median survival for limited-stage patients past four and a half years.
Roadblocks To Early Detection
Sometimes SCLC isn’t discovered because of symptoms but is found incidentally, during imaging for something else, such as a scan for pneumonia, a cardiac test or a routine exam for another reason.
Screening programs that have successfully caught early non-small cell lung cancers, like low-dose CT scans for heavy smokers, are less likely to catch SCLC early, because the disease tends to develop and spread in the intervals between annual scans.
This “window problem” means that even in patients who qualify for regular lung cancer screening, SCLC may appear and advance between visits. It underscores why any new respiratory symptom in a person with a smoking history should be checked quickly, not postponed until the next scheduled scan.
Promising Future Directions
Current USPSTF criteria for low-dose CT screening focus only on age and smoking history. That approach can miss people who develop lung cancer outside those rules, such as people younger than 50, those with lighter smoking histories, or former smokers who quit more than 15 years ago.
Researchers are working to close that early-detection gap. Some are testing risk-model-based screening that combines age, smoking history and other personal factors to pinpoint who is truly at highest risk.
Others are studying blood-based “liquid biopsies,” which look for fragments of tumor DNA or DNA methylation patterns in the blood, as well as tests of sputum and airway samples for changes in genes like TP53 and RB1, which typically drive SCLC. These approaches are still experimental, but they could one day flag cancer before it becomes visible on scans.
The hope is that screening will eventually shift from a once-a-year picture of the lungs to a more dynamic, personalized system that catches aggressive cancers like SCLC at a stage when they can still be cured.
Lung Cancer: The Early Detection Issue
Lung cancer forms when cancer cells develop in the tissues of the lung. It is the second most common form of cancer and the leading cause of cancer deaths in both men and women in the U.S., SurvivorNet experts say. It’s “completely asymptomatic,” says thoracic surgeon-in-chief at Temple University Health System Dr. Joseph Friedberg.
“It causes no issues until it has spread somewhere. So, if it spreads to the bones, it may cause pain. If it spreads to the brain, it may cause something not subtle, like a seizure,” Dr. Friedberg adds.
Scans such as X-rays can help doctors determine if a shadow appears, which can prompt further testing for lung cancer.
Some people with lung cancer may experience symptoms such as:
- A cough that doesn’t go away, that gets worse, or that brings up bloody phlegm
- Shortness of breath
- Fatigue
- Chest pain
- Hoarse voice
- Appetite loss
- Weight loss
If you are experiencing these kinds of symptoms consistently, contact your doctor for further tests.
There are two main types of lung cancer, which doctors group together based on how they act and how they’re treated:
- Non-small cell lung cancer (NSCLC) is the most common type and makes up about 85% of cases.
- Small cell lung cancer (SCLC) is less common, but it tends to grow faster than NSCLC and is treated very differently.
How Your Stage Is Determined
After an initial diagnosis of lung cancer all patients will have a staging workup to determine what stage of cancer they have and the best approach for treating their cancer.
For lung cancer, this can be quite extensive and include many tests and imaging studies. Typically, patients will have a combination of imaging studies including CT, MRI, and PET scans.
The goal of all of this imaging is to determine where cancer has spread and also where it has not spread.
Patients with stage 3 lung cancer will typically have imaging of the chest and tumor, a PET scan of the entire body to see if cancer has spread, and an MRI of the brain to see if cancer has spread into the brain.
In addition to imaging studies, patients will also have additional tests performed on the tissue obtained from the biopsy. These tests are conducted by a pathologist and look for aspects of the tumor that can be targeted for treatment. These tests include biomarker and genetic testing. Your doctors may order additional tests from what is covered here and it is important to discuss with your treatment team what is being ordered and why.
What is Molecular Testing and Next-Generation Sequencing?
Helping Patients Through Lung Cancer Surgery and Recovery
Before getting serious about lung cancer, oncologists take a closer look at the heart health of the patient.
“We’ll look at the carotid arteries, which are the blood vessels that supply blood to your brain,” Dr. Friedberg previously explained to SurvivorNet.
“In addition to smoking, which is the most common cause of lung cancer causing cancers, it also causes heart disease and other arterial diseases,” Dr. Friedberg added.
“We want to get the things to make sure that if surgery is appropriate, we, as best as we can humanly tell, have eliminated the possibilities or the likelihood that you’re going to have a heart attack or a stroke if we subject you to the surgery,” Dr. Friedberg said.
There are several types of surgery that can remove lung cancer, which include:
- Segmentectomy (removal of a small segment of the lung)
- Lobectomy (removal of a lobe of the lung)
- Pneumonectomy (removal of the entire lung)
The decision is largely based on the size of the tumor and where in your lung it is located.
“If the tumor is on the outer part of the lung and it’s small, you can get something called a wedge resection, which is a pizza pie-shaped resection of that lung,” Dr. Raja Flores, Chairman of the Department of Thoracic Surgery and the Steven and Ann Ames Professor in Thoracic Surgery for the Mount Sinai Health System, said.
“It removes the lung, and it spares a lot of the lung parenchyma, which is the functional part of the lung,” Dr. Flores added.
Although pneumonectomy removes the entire lung, Dr. Flores says not all patients can tolerate the procedure.
“It depends on how good their lung function really is, and many of the patients are smokers, so they have damaged their lungs, so you have to get these breathing tests before you go ahead and do any big lung operation on anybody,” Dr. Flores explained.
WATCH: Pain Management After Lung Cancer Surgery
As effective as lung cancer surgery can be, the recovery often feels like its own challenge. Melissa Culligan, a thoracic surgery nurse at the University of Maryland Medical Center, also spoke with SurvivorNet and said the hardest part usually begins once patients return home and have to manage pain on their own.
“I continue to learn that honesty to your patients and their family members while maintaining a healthy dose of hope is probably the most important thing for patients and their families as they’re going through cancer treatment,” Culligan explains.
That honesty helps people prepare for what recovery really looks like.
Culligan encourages patients to stay closely connected to their care team, especially when something feels off. As healing progresses, pain often shifts in both location and intensity, and she stresses that these changes are usually expected. Reaching out allows the team to either adjust pain management or reassure patients that their experience is normal.
As patients become more active, discomfort often increases. Culligan notes that this doesn’t mean anything is wrong; it’s simply part of the body’s recovery and rebuilding strength. She urges patients to continue taking their pain medication as prescribed while they heal.
“It’s critical after surgery and after any treatment that you do keep active and keep your body in the best possible condition along the way,” Culligan said.
Contributing: SurvivorNet Staff
Learn more about SurvivorNet's rigorous medical review process.
